The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000500358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
7/03/2026
Date registered
Help: Date registered
22/04/2026
Date last updated
Help: Date last updated
22/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Sex specific differences in outcomes following atrial fibrillation (AF) ablation versus medical therapy in patients with AF and heart failure
Scientific title
Evaluating QUantitative differences in women versus men with Atrial Fibrillation and Heart FaiLure undergoing AF ablation - The EQUAL-AF study
Additional trial identifiers [1] 316369 0
Nil known
Universal Trial Number (UTN)
Trial acronym
EQUAL-AF study
Related trial records

Health condition
Health condition(s) studied:
atrial fibrillation 340440 0
heart failure 340441 0
Condition category
Condition code
Cardiovascular 336655 336655 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
All participants will undergo a 5-week period of medical optimisation as part of standard care. The 5 week medical optimisation includes ensuring adequate AF rate control using medical therapy (rate control medications) and optimising heart failure therapy and fluid status (i.e. using diuretics for fluid overload, ensuring guideline-directed therapies for heart failure are incorporated as tolerated). Medical optimisation within the study protocol does not differ from routine AF and heart failure management. Management during this medical optimisation period follows routine clinical practice and does not differ from usual care.

AF catheter ablation (AF ablation)

Catheter ablation will be performed by a specialist Cardiac electrophysiologist using a standard ablation approach (this includes radiofrequency, cryoablation or pulsed field ablation, depending on local institutional practice) for atrial fibrillation. Following trans-septal access to the left atrium, electroanatomical mapping will be undertaken using a three-dimensional mapping system. Pulmonary vein isolation (PVI) will be performed, with delivery of ablation lesions to achieve electrical isolation of all pulmonary veins. Additional ablation (e.g. targeting non-pulmonary vein triggers or substrate modification) may be performed at the discretion of the treating operator in accordance with standard clinical practice.

The procedure will be performed by a cardiac electrophysiologist (a cardiologist with specialist training in cardiac rhythm disorders and catheter ablation) in an accredited electrophysiology laboratory. The approximate procedure duration will be between 1-3 hours per participant, depending on institutional practice and ablation technology utilized.

If allocated to ablation, the intervention (ablation) will be delivered as a single procedure during the the study period. Repeat ablation procedures may be performed if clinically indicated during follow-up, according to standard care.

The procedure will be conducted in a hospital-based electrophysiology laboratory within participating tertiary referral centres.
Intervention code [1] 333030 0
Treatment: Devices
Description of the comparator or control
Comparator arm: Medical Therapy (Pharmacological Rate ± Rhythm Control)

Medical therapy will consist of guideline-directed pharmacological management for atrial fibrillation, including rate control and/or rhythm control strategies, as determined by the treating physician in accordance with standard clinical practice.

For pharmacological management:
Medications used:
Rate control may include beta-blockers (e.g. metoprolol, bisoprolol, nebivolol), non-dihydropyridine calcium channel blockers (e.g. diltiazem, verapamil), and/or digoxin.
Rhythm control may include antiarrhythmic drugs such as amiodarone, sotalol, or flecainide, selected based on patient characteristics and after ensuring no overt contraindications.

Dose administered:
Medication type and dosing will be individualised and titrated to achieve target heart rate and/or rhythm control, in accordance with guideline-recommended dosing ranges and clinical response. Typically, this will involve achieving a resting heart rate </=90bpm.

Duration of administration:
Pharmacological therapy will be administered continuously throughout the study follow-up period (12 months post randomisation), with adjustments permitted as clinically indicated and with remote rhythm monitoring (holter monitor) to assess the adequacy of rate control.

Mode of administration:
Medications will be administered orally in tablet or capsule form. Intravenous administration may be used transiently in acute clinical settings (e.g. hospitalisation) as per standard care.

Monitoring of adherence:
Adherence will be assessed through routine clinical follow-up, including patient self-report, medication reconciliation at study visits, and review of medical records. No additional adherence-specific interventions will be mandated as part of the study.
Control group
Active

Outcomes
Primary outcome [1] 344663 0
The primary outcome will be a hierarchical composite using a Win Ratio and including: • All-cause death (time to event) • Time to first cardiovascular (CV) hospitalisation • Any change in LVEF >10% from baseline • Any change in NT-proBNP >10% from baseline • Any change in 6-minute walk distance >10% from baseline (measure of functional capacity) • Any change of New York Heart Association Class by >1 class from baseline • Any change in quality of life score >10% from baseline • Escalation of heart failure therapy
Timepoint [1] 344663 0
All outcome measures will be assessed relative to the timing of the intervention and study enrolment. Baseline assessments will be performed prior to randomisation and prior to delivery of the intervention (catheter ablation or initiation/titration/continuation of medical therapy). Follow-up assessments will be conducted at prespecified intervals during the study period, including at approximately 3, 6 and 12 months post-enrolment. Clinical outcomes (all-cause death and cardiovascular hospitalisation) will be assessed continuously from the time of enrolment through to 12 months of follow-up using medical records. Structural and biomarker outcomes, including LVEF and NT-proBNP, will be assessed at baseline and repeated at 12 months. Functional capacity (6-minute walk test), New York Heart Association (NYHA) class, and quality of life will be assessed at baseline and at 12 month follow-up visits. Medication use and heart failure therapy escalation will be assessed at each follow-up visit (3, 6 and 12 months) through medication review and medical record assessment.
Secondary outcome [1] 458770 0
Sex-based differences between women and men undergoing catheter ablation with respect to the degree of LVEF change from baseline to 12 months following CA
Timepoint [1] 458770 0
Baseline (prior to ablation) and 12 months post ablation.
Secondary outcome [2] 459926 0
Sex-based differences between women and men undergoing catheter ablation with respect to the degree of reverse cardiac remodeling at 12 months
Timepoint [2] 459926 0
Baseline (pre-ablation) and 12 months post ablation
Secondary outcome [3] 459927 0
Sex-based differences between women and men undergoing catheter ablation with respect to change in cardiac biomarkers (NT-proBNP) from baseline to 12 months
Timepoint [3] 459927 0
Baseline (prior to ablation) and 12 months post ablation
Secondary outcome [4] 459928 0
Sex-based differences between women and men undergoing catheter ablation with respect to arrhythmia outcomes at 12 months
Timepoint [4] 459928 0
Remote rhythm monitoring will take place from enrolment (medical arm) or from ablation (intervention arm) and will be continuous where feasible (AliveCor, loop recorder or personal device) or intermittent (Holter monitor at baseline, 3m, 6m and 12m in the medical arm) for the 12-month duration of the study period.
Secondary outcome [5] 459929 0
Sex-based differences between women and men undergoing catheter ablation with respect to procedural complications
Timepoint [5] 459929 0
Assessed at the time of the ablation procedure, after the procedure during the index admission or up to 30 days after the procedure, as applicable.
Secondary outcome [6] 459930 0
Sex-based differences between women and men undergoing catheter ablation with respect to healthcare utilization including a composite of: need for electrical cardioversion, repeat ablation procedures, unplanned heart failure visits or hospital admissions
Timepoint [6] 459930 0
Assessed from enrolment to the conclusion of the study (12 months post ablation)
Secondary outcome [7] 459931 0
Sex-based differences between women and men undergoing catheter ablation with respect to electroanatomical characteristics at ablation: global tissue voltage.
Timepoint [7] 459931 0
This will be assessed at the time of the ablation procedure.
Secondary outcome [8] 459934 0
Comparison of other outcomes in women undergoing catheter ablation vs medical therapy with respect to reverse cardiac remodeling (change in left atrial size)
Timepoint [8] 459934 0
Baseline (at enrolment or prior to ablation) and at 12 months (12 months post ablation or post enrolment, depending on allocation)
Secondary outcome [9] 459935 0
Comparison of AF burden in women undergoing catheter ablation vs medical rate control at 12 months
Timepoint [9] 459935 0
Continuous monitoring for loop recorders or personal devices. Baseline, 3m, 6m and 12m for Holter monitoring.
Secondary outcome [10] 459936 0
Comparison of change in AF burden from baseline to 12 months in women undergoing catheter ablation versus medical therapy.
Timepoint [10] 459936 0
Continuous for AliveCor device, personal device or loop recorder. Holter monitoring at baseline, 3m, 6m and 12 months.
Secondary outcome [11] 459937 0
Comparison of change in functional capacity in women undergoing catheter ablation versus medical therapy functional capacity from baseline to 12 months
Timepoint [11] 459937 0
Baseline (enrolment or pre-ablation) and 12 months (12m post ablation or 12m post enrolment, depending on allocation).
Secondary outcome [12] 459938 0
Comparison of heart failure symptoms in women undergoing catheter ablation versus medical therapy at 12 months
Timepoint [12] 459938 0
Baseline (at enrolment or pre ablation), 6m and 12m (6 and 12m post ablation or post enrolment, depending on allocation).
Secondary outcome [13] 460210 0
Sex-based differences between women and men undergoing catheter ablation with respect to AF burden at 12 months
Timepoint [13] 460210 0
Remote rhythm monitoring will take place from ablation to follow up and will be continuous where feasible (AliveCor, loop recorder or personal device) or intermittent (Holter monitor at baseline, 3m, 6m and 12m) for the duration of the study (12 months).
Secondary outcome [14] 460211 0
Sex-based differences between women and men undergoing catheter ablation with respect to any change in the degree of valvular regurgitation
Timepoint [14] 460211 0
Baseline and 12 months
Secondary outcome [15] 460212 0
Comparison of quality of life in women undergoing catheter ablation versus medical therapy at 12 months
Timepoint [15] 460212 0
Baseline (at enrolment), 6m and 12m. (6m and 12m pertain to time from enrolment (medical arm) or time from ablation (intervention arm)).
Secondary outcome [16] 460213 0
Sex-based differences between women and men undergoing catheter ablation with respect to electroanatomical characteristics at ablation: regional tissue voltage
Timepoint [16] 460213 0
This will be assessed at the time of the ablation procedure.

Eligibility
Key inclusion criteria
1. Age 18 years or older
2. Documented atrial fibrillation (paroxysmal or persistent)
3. Heart failure with mid-range or preserved left ventricular ejection fraction (LVEF 40% or above on echocardiography or cardiac MRI)
4. Symptoms attributable to atrial fibrillation and/or heart failure
5. Suitable candidate for both catheter ablation and medical rhythm control therapy as determined by the treating cardiologist
6. Receiving guideline-directed medical therapy for heart failure (as tolerated)
7. Able to provide written informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Contraindication to CMR (i.e. eGFR<25; 5 years deemed unlikely to restore or maintain sinus rhythm)
3. LVEF <40%
4. Other acute reversible cause of heart failure (uncontrolled thyroid disease, excessive alcohol, active myocarditis)
5. Planned alternate cardiac intervention within 12 months of enrolment (i.e. valvular intervention, coronary artery bypass graft surgery)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment using sealed opaque envelopes.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Stratified allocation by centre to ensure appropriate and equitable female representation across recruitment sites. Computerised sequence generation taking into account study site
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29246 0
The Alfred - Melbourne
Recruitment hospital [2] 29247 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [3] 29383 0
The Canberra Hospital - Garran
Recruitment postcode(s) [1] 45555 0
3004 - Melbourne
Recruitment postcode(s) [2] 45556 0
3050 - Parkville
Recruitment postcode(s) [3] 45702 0
2605 - Garran

Funding & Sponsors
Funding source category [1] 320977 0
Hospital
Name [1] 320977 0
Alfred Hospital
Country [1] 320977 0
Australia
Primary sponsor type
Hospital
Name
Alfred Hospital
Address
Country
Australia
Secondary sponsor category [1] 324063 0
None
Name [1] 324063 0
Address [1] 324063 0
Country [1] 324063 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319862 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319862 0
Ethics committee country [1] 319862 0
Australia
Date submitted for ethics approval [1] 319862 0
12/01/2026
Approval date [1] 319862 0
03/04/2026
Ethics approval number [1] 319862 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147562 0
Dr Louise Segan
Address 147562 0
The Alfred Hospital, 55 Commercial Rd, Prahran VIC 3004
Country 147562 0
Australia
Phone 147562 0
+61390763352
Fax 147562 0
Email 147562 0
Contact person for public queries
Name 147563 0
Louise Segan
Address 147563 0
The Alfred Hospital, 55 Commercial Rd, Prahran VIC 3004
Country 147563 0
Australia
Phone 147563 0
+61390762000
Fax 147563 0
Email 147563 0
Contact person for scientific queries
Name 147564 0
Louise Segan
Address 147564 0
The Alfred Hospital, 55 Commercial Rd, Prahran VIC 3004
Country 147564 0
Australia
Phone 147564 0
+61390762000
Fax 147564 0
Email 147564 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: In order to maintain strict confidentiality of individual participant information, individual participant data will not be available. However, aggregrate deidentified data may be available upon reasonable request.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
ProtocolNo EQUAL-AF study protocol v7_clean copy.pdf

Documents added automatically
No additional documents have been identified.